X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Abbott India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs ABBOTT INDIA - Comparison Results

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA ABBOTT INDIA AJANTA PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 20.9 32.8 63.7% View Chart
P/BV x 9.1 8.2 110.4% View Chart
Dividend Yield % 0.7 0.8 81.0%  

Financials

 AJANTA PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
ABBOTT INDIA
Mar-16
AJANTA PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1,7206,015 28.6%   
Low Rs1,1033,707 29.8%   
Sales per share (Unadj.) Rs194.61,236.9 15.7%  
Earnings per share (Unadj.) Rs45.2122.2 37.0%  
Cash flow per share (Unadj.) Rs50.3129.0 39.0%  
Dividends per share (Unadj.) Rs8.0035.00 22.9%  
Dividend yield (eoy) %0.60.7 78.7%  
Book value per share (Unadj.) Rs132.0521.2 25.3%  
Shares outstanding (eoy) m88.7721.25 417.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.33.9 184.6%   
Avg P/E ratio x31.239.8 78.5%  
P/CF ratio (eoy) x28.137.7 74.5%  
Price / Book Value ratio x10.79.3 114.6%  
Dividend payout %17.728.6 61.8%   
Avg Mkt Cap Rs m125,299103,296 121.3%   
No. of employees `000NA3.0 0.0%   
Total wages/salary Rs m2,5703,370 76.3%   
Avg. sales/employee Rs ThNM8,891.8-  
Avg. wages/employee Rs ThNM1,140.0-  
Avg. net profit/employee Rs ThNM878.3-  
INCOME DATA
Net Sales Rs m17,27526,284 65.7%  
Other income Rs m166504 33.0%   
Total revenues Rs m17,44226,789 65.1%   
Gross profit Rs m5,8073,665 158.4%  
Depreciation Rs m451144 312.0%   
Interest Rs m498 603.7%   
Profit before tax Rs m5,4744,017 136.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,4601,421 102.7%   
Profit after tax Rs m4,0142,596 154.6%  
Gross profit margin %33.613.9 241.1%  
Effective tax rate %26.735.4 75.4%   
Net profit margin %23.29.9 235.2%  
BALANCE SHEET DATA
Current assets Rs m7,63914,446 52.9%   
Current liabilities Rs m2,7154,725 57.5%   
Net working cap to sales %28.537.0 77.1%  
Current ratio x2.83.1 92.0%  
Inventory Days Days4351 84.1%  
Debtors Days Days7920 402.2%  
Net fixed assets Rs m6,9141,113 621.2%   
Share capital Rs m177213 83.2%   
"Free" reserves Rs m11,44210,808 105.9%   
Net worth Rs m11,72111,076 105.8%   
Long term debt Rs m1490-   
Total assets Rs m14,81416,241 91.2%  
Interest coverage x112.9497.0 22.7%   
Debt to equity ratio x00-  
Sales to assets ratio x1.21.6 72.1%   
Return on assets %27.416.0 171.0%  
Return on equity %34.223.4 146.1%  
Return on capital %46.536.3 128.0%  
Exports to sales %55.10.6 8,969.9%   
Imports to sales %6.012.6 47.5%   
Exports (fob) Rs m9,527162 5,895.5%   
Imports (cif) Rs m1,0383,322 31.2%   
Fx inflow Rs m10,422268 3,888.7%   
Fx outflow Rs m1,6783,927 42.7%   
Net fx Rs m8,744-3,659 -238.9%   
CASH FLOW
From Operations Rs m3,2642,514 129.8%  
From Investments Rs m-2,093-800 261.8%  
From Financial Activity Rs m-1,186-803 147.7%  
Net Cashflow Rs m-15912 -1.6%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 1.6 7.9 19.6%  
FIIs % 7.6 0.1 7,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 17.1 99.4%  
Shareholders   20,968 18,270 114.8%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   J.B.CHEMICALS  SUVEN LIFE  CIPLA  WOCKHARDT LTD.  IPCA LABS  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS